SG11201808270PA - Substituted indoline derivatives as dengue viral replication inhibitors - Google Patents
Substituted indoline derivatives as dengue viral replication inhibitorsInfo
- Publication number
- SG11201808270PA SG11201808270PA SG11201808270PA SG11201808270PA SG11201808270PA SG 11201808270P A SG11201808270P A SG 11201808270PA SG 11201808270P A SG11201808270P A SG 11201808270PA SG 11201808270P A SG11201808270P A SG 11201808270PA SG 11201808270P A SG11201808270P A SG 11201808270PA
- Authority
- SG
- Singapore
- Prior art keywords
- leuven
- international
- compounds
- dengue viral
- janssen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010 11111 0111011110011111B1011001111101111011 1111 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/167953 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CO7D 209/26 (2006.01) A61P 31/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/404 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2017/057663 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 31 March 2017 (31.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 16163281.5 31 March 2016 (31.03.2016) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicants: JANSSEN PHARMACEUTICALS, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 1125 Trenton-Harbourton Road, Titusville, NJ TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, New Jersey 08560 (US). KATHOLIEKE UNI- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, VERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus 5105, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 3000 Leuven (BE). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: BARDIOT, Dorothee Alice Marie-Eve; c/o SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — Cistim Leuven vzw, Gaston Geenslaan 2, 3001 Leuven GW, KM, ML, MR, NE, SN, TD, TG). — (Heverlee) (BE). BONFANTI, Jean-Francois; c/o Declarations under Rule 4.17: _ Janssen-Cilag, 1 rue Camille Desmoulins, TSA 91003, — as to applicant's entitlement to apply for and be granted a 92787 Issy-les-Moulineaux Cedex 9 (FR). KESTELEYN, 4.1700) = patent (Rule c/o Janssen Bart Rudolf Romanie; Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse MARCHAND, Published: (BE). Arnaud Didier M; Cistim Leuven Gaston Geens- c/o vzw, - with international search report (Art. 21(3)) laan 2, 3001 Leuven RABOISSON, = (Heverlee) (BE). Pierre Jean-Marie Bernard; c/o Janssen Pharmaceutica — with sequence listing part of description (Rule 5.2(a)) NV, Turnhoutseweg 30, 2340 Beerse (BE). (74) Agent: VERBERCKMOES, Filip; J&J Patent Law De- = partment, Turnhoutseweg 30, 2340 Beerse (BE). = = = = = = = = 1-1 M kr) 0\ IN 1-1 (54) Title: SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS 1-1 C (57) : The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections ei by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or 0 prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination prepara- tions of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16163281 | 2016-03-31 | ||
| PCT/EP2017/057663 WO2017167953A1 (en) | 2016-03-31 | 2017-03-31 | Substituted indoline derivatives as dengue viral replication inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808270PA true SG11201808270PA (en) | 2018-10-30 |
Family
ID=55646444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808270PA SG11201808270PA (en) | 2016-03-31 | 2017-03-31 | Substituted indoline derivatives as dengue viral replication inhibitors |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10913716B2 (en) |
| EP (1) | EP3436436B1 (en) |
| JP (1) | JP6931357B2 (en) |
| KR (1) | KR102359735B1 (en) |
| CN (1) | CN109195949B (en) |
| AU (1) | AU2017240077A1 (en) |
| BR (1) | BR112018069601A2 (en) |
| CA (1) | CA3013407A1 (en) |
| CL (1) | CL2018002718A1 (en) |
| CO (1) | CO2018008421A2 (en) |
| CR (1) | CR20180496A (en) |
| EA (1) | EA201892216A1 (en) |
| EC (1) | ECSP18073366A (en) |
| ES (1) | ES2923771T3 (en) |
| IL (1) | IL261943A (en) |
| MA (1) | MA44498A (en) |
| MX (1) | MX2018011788A (en) |
| PH (1) | PH12018502016A1 (en) |
| SG (1) | SG11201808270PA (en) |
| WO (1) | WO2017167953A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| EP3436436B1 (en) | 2016-03-31 | 2022-05-11 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20180495A (en) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | INDOL DERIVATIVES REPLACED AS VIRAL REPLICATION INHIBITORS OF DENGUE |
| JOP20170069B1 (en) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| CA3013408A1 (en) | 2016-04-01 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| KR102625991B1 (en) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | Substituted indoline derivatives as dengue virus replication inhibitors |
| CN110691773B (en) | 2017-05-22 | 2023-06-23 | 杨森制药公司 | Substituted indoline derivatives as dengue virus replication inhibitors |
| CN109485596A (en) * | 2018-12-19 | 2019-03-19 | 山东理工职业学院 | A kind of preparation method of the dengue virus inhibitor containing indoline |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001520998A (en) | 1997-10-27 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | Morpholino-N-ethyl ester prodrug of indole sPLA2 inhibitor |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| US20050074457A1 (en) | 2001-12-12 | 2005-04-07 | Adeela Kamal | Assays and implements for determining and modulating hsp90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| RU2007130896A (en) | 2005-01-14 | 2009-02-20 | Дженелэбс Текнолоджиз, Инк. (Us) | INDOLY DERIVATIVES FOR TREATING VIRAL INFECTIONS |
| JP2008530124A (en) | 2005-02-09 | 2008-08-07 | ミジェニックス インコーポレイテッド | Compositions and methods for treating or preventing flavivirus infections |
| CA2726985A1 (en) | 2008-06-03 | 2009-12-10 | Siga Technologies, Inc. | Small molecule inhibitors for the treatment or prevention of dengue virus infection |
| TWI532497B (en) * | 2008-08-11 | 2016-05-11 | 曼凱公司 | Use of ultrarapid acting insulin |
| US8143259B2 (en) * | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
| TWI453207B (en) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith |
| EP2393359A4 (en) | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| CN102712632A (en) | 2010-01-15 | 2012-10-03 | 吉里德科学公司 | Inhibitors of flaviviridae viruses |
| WO2011120025A1 (en) | 2010-03-26 | 2011-09-29 | Glaxo Group Limited | Indazolyl-pyrimidines as kinase inhibitors |
| JP5716205B2 (en) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | Composition for inhibiting glucosidase activity and screening method thereof |
| GB201116559D0 (en) * | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| NZ717629A (en) | 2013-10-23 | 2021-12-24 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| NZ723762A (en) | 2014-01-31 | 2023-03-31 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2’ groups as factor xia inhibitors |
| BR112017006708A2 (en) | 2014-10-01 | 2017-12-26 | Janssen Pharmaceuticals Inc | mono- or disubstituted indoles as inhibitors of dengue viral replication |
| NO2721243T3 (en) | 2014-10-01 | 2018-10-20 | ||
| SG11201702463YA (en) | 2014-10-01 | 2017-04-27 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20150335B1 (en) | 2015-01-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | indole derivatives as dengue viral replication inhibitors |
| AR103680A1 (en) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | BACE1 SELECTIVE INHIBITORS |
| JOP20160086B1 (en) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JO3633B1 (en) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| JOP20160198B1 (en) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| ES2907686T3 (en) | 2015-11-03 | 2022-04-26 | Zoetis Services Llc | Sol-gel polymeric compounds and their uses |
| EP3436436B1 (en) | 2016-03-31 | 2022-05-11 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20180495A (en) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | INDOL DERIVATIVES REPLACED AS VIRAL REPLICATION INHIBITORS OF DENGUE |
| KR102388440B1 (en) | 2016-03-31 | 2022-04-19 | 다케다 야쿠힌 고교 가부시키가이샤 | heterocyclic compounds |
| CA3013408A1 (en) | 2016-04-01 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
| BR112018070073A2 (en) | 2016-04-01 | 2019-02-12 | Kite Pharma, Inc. | chimeric antigen and t-cell receptors and methods of use |
| CN109641956A (en) | 2016-04-01 | 2019-04-16 | 美国安进公司 | The Chimerical receptor and its application method of FLT3 |
| CN109069512B (en) | 2016-04-01 | 2022-06-14 | 西格诺药品有限公司 | Substituted aminopurine compounds, compositions thereof, and related methods of treatment |
| JOP20170069B1 (en) * | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20180480A (en) | 2016-04-01 | 2019-04-02 | Amgen Inc | CHEMICAL RECEPTORS AND METHODS OF USE OF THE SAME |
| PE20181898A1 (en) | 2016-04-01 | 2018-12-11 | Basf Se | BICYCLE COMPOUNDS |
| JOP20180026A1 (en) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | Substituted indoline derivatives as dengue viral replication inhibitors |
| JOP20180025B1 (en) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | Substituted indoline derivatives as dengue viral replication inhibitors |
| CN110691773B (en) | 2017-05-22 | 2023-06-23 | 杨森制药公司 | Substituted indoline derivatives as dengue virus replication inhibitors |
| KR102625991B1 (en) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | Substituted indoline derivatives as dengue virus replication inhibitors |
| CN109485596A (en) * | 2018-12-19 | 2019-03-19 | 山东理工职业学院 | A kind of preparation method of the dengue virus inhibitor containing indoline |
-
2017
- 2017-03-31 EP EP17714475.5A patent/EP3436436B1/en active Active
- 2017-03-31 WO PCT/EP2017/057663 patent/WO2017167953A1/en active Application Filing
- 2017-03-31 MA MA044498A patent/MA44498A/en unknown
- 2017-03-31 EA EA201892216A patent/EA201892216A1/en unknown
- 2017-03-31 SG SG11201808270PA patent/SG11201808270PA/en unknown
- 2017-03-31 CA CA3013407A patent/CA3013407A1/en not_active Abandoned
- 2017-03-31 KR KR1020187026918A patent/KR102359735B1/en active IP Right Grant
- 2017-03-31 AU AU2017240077A patent/AU2017240077A1/en not_active Abandoned
- 2017-03-31 MX MX2018011788A patent/MX2018011788A/en unknown
- 2017-03-31 ES ES17714475T patent/ES2923771T3/en active Active
- 2017-03-31 BR BR112018069601A patent/BR112018069601A2/en not_active Application Discontinuation
- 2017-03-31 US US16/088,459 patent/US10913716B2/en active Active
- 2017-03-31 CR CR20180496A patent/CR20180496A/en unknown
- 2017-03-31 JP JP2018550333A patent/JP6931357B2/en active Active
- 2017-03-31 CN CN201780021312.2A patent/CN109195949B/en active Active
-
2018
- 2018-08-10 CO CONC2018/0008421A patent/CO2018008421A2/en unknown
- 2018-09-20 PH PH12018502016A patent/PH12018502016A1/en unknown
- 2018-09-25 CL CL2018002718A patent/CL2018002718A1/en unknown
- 2018-09-26 IL IL261943A patent/IL261943A/en unknown
- 2018-09-28 EC ECSENADI201873366A patent/ECSP18073366A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN109195949B (en) | 2021-09-17 |
| PH12018502016A1 (en) | 2019-07-15 |
| US10913716B2 (en) | 2021-02-09 |
| CN109195949A (en) | 2019-01-11 |
| KR20180132056A (en) | 2018-12-11 |
| CO2018008421A2 (en) | 2018-10-22 |
| EP3436436A1 (en) | 2019-02-06 |
| JP2019510027A (en) | 2019-04-11 |
| EA201892216A1 (en) | 2019-03-29 |
| WO2017167953A1 (en) | 2017-10-05 |
| CA3013407A1 (en) | 2017-10-05 |
| CR20180496A (en) | 2018-12-06 |
| MX2018011788A (en) | 2019-05-20 |
| AU2017240077A1 (en) | 2018-08-09 |
| KR102359735B1 (en) | 2022-02-08 |
| IL261943A (en) | 2018-10-31 |
| US20200339511A1 (en) | 2020-10-29 |
| ECSP18073366A (en) | 2018-10-31 |
| ES2923771T3 (en) | 2022-09-30 |
| EP3436436B1 (en) | 2022-05-11 |
| JP6931357B2 (en) | 2021-09-01 |
| CL2018002718A1 (en) | 2018-12-14 |
| MA44498A (en) | 2019-02-06 |
| BR112018069601A2 (en) | 2019-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds |